Breaking News:

Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis. Learn more at www.abivax.com/press-releases/

Share Profile

Abivax SA has been listed on the Paris Stock Exchange since 26 June 2015.

  • ISIN code: FR0012333284
  • Symbol: ABVX
  • ICB Classification: Healthcare 4000/ Biotechnology 4573
  • Market: Euronext Paris-Compartment B
  • Type of Listing: continuous
  • Number of shares: 16,692,268 as of July 30, 2021
  • Indices: CAC ALL SHARES, CAC All-Tradable, CAC MID&SMALL, CAC SMALL, CAC Health Care, CAC Pharma & Bio, and Next Biotech
  • Eligible to French PEA PME

Analysts

Oddo BHF:

Martial Descoutures

LifeSci Capital | Alpha Series:

Adam Evertts

Bryan, Garnier & Co:

Jean-Jacques Le Fur

goetzpartners securities:

Chris Redhead

Degroof Petercam:

David Seynnaeve

Kepler Cheuvreux:

Damien Choplain

Portzamparc:

Christophe Dombu

Investor Contact

Ligia Vela-Reid LifeSci Advisors lvela-reid@lifesciadvisors.com +44 (0) 7413 825310